ARDS Aridis Pharmaceuticals has 2 Phase 3 Clinical Trials for 2022, one Phase 2a study, a fully human monoclonal antibody (mAb) cocktail against COVID and a funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19.
And the Market Cap is only...
ARDS Aridis Pharmaceuticals received a grant award from the Bill & Melinda Gates Foundation to evaluate the application of Aridis' inhaled formulation technology to deliver cost-effective monoclonal antibodies (mAbs) against influenza and SARS-CoV2.
Aridis Pharmaceuticals is a stock with a mk cap of only 28.249Mil.
Before Aridis, Bill & Melinda Gates Foundation...
Aridis Pharmaceuticals announced first Investor call of 2022 for today, after the closing bell.
Exiting pipeline with 2 phase 3 drugs and their monoclonal antibody cocktail.
AstraZeneca PLC (AZN) has a stake in this company.
CEO has co-developed several drug which have been sold to Astra Zeneca, Megabits and MedImmune.
Aridis Pharmaceuticals can be a potential...
Analyst Vernon Bernardino from H.C. Wainwright reiterated a buy rating and $19 price target on ARDS: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."
Aridis Pharmaceuticals Inc 's monoclonal...
The chart speaks for itself: ARDS is in a massive bullish divergence at all time low levels from which can explode anytime soon!
Recently, analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS , told investors that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class...
Analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS, told investors Wednesday that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants...
